MONTREAL, QC / ACCESSWIRE / October 7, 2020 / Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:MDP)(OTCQX:MEDXF) today announced that it will be presenting at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th – 16th, 2020.
Ken d’Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus are scheduled to present on Wednesday, October 14th at 12:30 p.m., Eastern Time. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2134/37963. One-on-one meetings will be held throughout the conference via video conference calls.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email Angie.Goertz@IssuerDirect.com.
About the MicroCap Rodeo Best Ideas Bowl
The MicroCap Rodeo is back with its first ever “Best Ideas Bowl.” This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. For more information please visit our website: https://microcaprodeo.com/.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.
For more information, please contact:
Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202
E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com
Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Medexus Pharmaceuticals Inc.
View source version on accesswire.com:
https://www.accesswire.com/609472/Medexus-to-Present-at-MicroCap-Rodeo-Best-Ideas-Bowl-on-October-14th
Charlotte, North Carolina--(Newsfile Corp. - January 8, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
RXNT celebrated the holiday season by giving back to four worthy, community-driven charities, all with…
TORRINGTON, Conn., Jan. 8, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…
LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- Could this be the year your fitness goals…
Investment will advance Net Health's mission to provide patient-centric care by streamlining administrative processes for…
NEW YORK CITY, NEW YORK / ACCESSWIRE / January 8, 2025 / Black Book™ Market…